Compare RHI & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RHI | HAE |
|---|---|---|
| Founded | 1948 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.6B |
| IPO Year | 1994 | 1996 |
| Metric | RHI | HAE |
|---|---|---|
| Price | $24.05 | $59.48 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 9 |
| Target Price | $30.33 | ★ $85.38 |
| AVG Volume (30 Days) | ★ 2.6M | 600.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.49% | N/A |
| EPS Growth | N/A | ★ 44.54 |
| EPS | 1.33 | ★ 2.46 |
| Revenue | ★ $5,378,506,000.00 | $910,373,000.00 |
| Revenue This Year | $1.27 | N/A |
| Revenue Next Year | $5.95 | $5.31 |
| P/E Ratio | ★ $18.68 | $23.74 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.83 | $47.32 |
| 52 Week High | $51.55 | $87.32 |
| Indicator | RHI | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 47.13 | 51.95 |
| Support Level | $22.08 | $48.47 |
| Resistance Level | $25.19 | $66.86 |
| Average True Range (ATR) | 1.16 | 1.73 |
| MACD | 0.20 | 0.42 |
| Stochastic Oscillator | 54.29 | 80.92 |
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.